Insmed

$1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today - Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.06% on an annualized basis producing an average annual return of 24.7%. Currently, Insmed has a market capitalization of $25.54 billion.

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

Insmed Incorporated (NASDAQ:INSM) announced on September 21 that the FDA accepted its supplemental application for ARIKAYCE and granted priority review, setting January 28, 2027, as the target decision date. The application seeks full approval and broader use alongside other antibiotics for Mycobacterium avium complex, or MAC, lung disease, a serious bacterial infection. ARIKAYCE currently has […]

Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target

Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case (NASDAQ:INSM)

Insmed stock price target maintained at $195 by Mizuho on FDA review

Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative?

Insmed has reported that the U.S. FDA previously accepted its supplemental New Drug Application for ARIKAYCE for MAC lung disease under Priority Review, with a target action date of January 28, 2027, based on positive Phase 3b ENCORE data fulfilling a key post-marketing requirement. The ENCORE trial results could allow ARIKAYCE to be used earlier in the MAC disease course and support label expansion discussions in Japan, potentially broadening its treatment reach while maintaining a safety...